Hypoxia Gene Expression Signatures as Prognostic and Predictive Markers in Head and Neck Radiotherapy

Seminars in Radiation Oncology

Volumn 22, Issue 2, 2012, Pages 119-127

  Toustrup, Kasper ^a   Sørensen, Brita S ^a   Alsner, Jan ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; ACETAMIDE; CARBOGEN; CISPLATIN; COMPLEMENTARY DNA; COPPER COMPLEX; FORMALDEHYDE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NIMORAZOLE; PARAFFIN; PIMONIDAZOLE; PLACEBO; TIRAPAZAMINE;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CARBOHYDRATE METABOLISM; CHEMORADIOTHERAPY; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC PROCEDURES; HEAD AND NECK CARCINOMA; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; HYPOXIA GENE EXPRESSION SIGNATURE; OXYGEN BREATHING; OXYGEN TENSION; OXYGEN TRANSPORT; PH; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REPRODUCIBILITY; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR MICROENVIRONMENT; WART VIRUS;

ANOXIA; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84857555243     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.12.006     Document Type: Review

References (74)

1. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26:638-648.
2. Bussink J., Kaanders J.H., van der Kogel A.J. Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003, 67:3-15.
3. Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007, 25:4066-4074.
4. Ang K.K. More lessons learned from the suffocation of hypoxia. J Clin Oncol 2010, 28:2941-2943.
5. Kaanders J.H., Terhaard C., Doornaert P., et al. Outcome after ARCON for clinical stage T2-4 laryngeal cancer: Early results of a phase III randomized trial. Radiother Oncol 2010, 96:158.
6. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46:135-146.
7. Rischin D., Peters L.J., O'Sullivan B., et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010, 28:2989-2995.
8. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-A systematic review and meta-analysis. Radiother Oncol 2011, 100:22-32.
9. Brown J.M. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993, 67:1163-1170.
10. Brown J.M. The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain memorial award lecture. Cancer Res 1999, 59:5863-5870.
11. Kaanders J.H., Bussink J., van der Kogel A.J. Arcon: A novel biology-based approach in radiotherapy. Lancet Oncol 2002, 3:728-737.
12. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 52:769-778.
13. Rischin D., Hicks R.J., Fisher R., et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol 2006, 24:2098-2104.
14. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002, 62:7066-7074.
15. Bussink J., van der Kogel A.J., Kaanders J.H. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome: In regard to Evans et al. (Int J Radiat Oncol Biol Phys 69:1024-1031, 2007). Int J Radiat Oncol Biol Phys 2008, 70:1616.
16. Rademakers S., Hoogsteen I.J., Marres H.A., et al. Predictive value of hypoxia-related markers in head and neck cancer treated with ARCON. Radiother Oncol 2010, 96:77.
17. Le Q.T., Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev 2008, 27:351-362.
18. Doll C.M., Milosevic M., Pintilie M., et al. Estimating hypoxic status in human tumors: A simulation using Eppendorf oxygen probe data in cervical cancer patients. Int J Radiat Oncol Biol Phys 2003, 55:1239-1246.
19. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 1999, 151:580-589.
20. Gross M.W., Karbach U., Groebe K., et al. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 1995, 61:567-573.
21. Busk M., Horsman M.R., Jakobsen S., et al. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008, 35:2294-2303.
22. Evans S.M., Hahn S., Pook D.R., et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000, 60:2018-2024.
23. Holland J.P., Lewis J.S., Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging 2009, 53:193-200.
24. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
25. Eschmann S.M., Paulsen F., Reimold M., et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005, 46:253-260.
26. Moon E.J., Brizel D.M., Chi J.T., et al. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007, 9:1237-1294.
27. Vordermark D., Brown J.M. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?. Strahlenther Onkol 2003, 179:801-811.
28. Jonathan R.A., Wijffels K.I., Peeters W., et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 2006, 79:288-297.
29. Nordsmark M., Eriksen J.G., Gebski V., et al. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 2007, 83:389-397.
30. Eriksen J.G., Overgaard J. Lack of prognostic and predictive value of ca IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study. Radiother Oncol 2007, 83:383-388. Danish Head and Neck Cancer Study Group (DAHANCA).
31. De Schutter H., Landuyt W., Verbeken E., et al. The prognostic value of the hypoxia markers ca IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005, 5:42.
32. Oliver R.J., Woodwards R.T., Sloan P., et al. Prognostic value of facilitative glucose transporter glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC translational research fund studies. Eur J Cancer 2004, 40:503-507.
33. Erler J.T., Bennewith K.L., Nicolau M., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
34. Le Q.T., Harris J., Magliocco A.M., et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol 2009, 27:4281-4286.
35. Le Q.T., Sutphin P.D., Raychaudhuri S., et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003, 9:59-67.
36. Le Q.T., Kong C., Lavori P.W., et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007, 69:167-175.
37. Overgaard J., Eriksen J.G., Nordsmark M., et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6:757-764.
38. Semenza G.L. HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010, 20:51-56.
39. Adams J.M., Difazio L.T., Rolandelli R.H., et al. HIF-1: A key mediator in hypoxia. Acta Physiol Hung 2009, 96:19-28.
40. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
41. Janssen H.L., Haustermans K.M., Sprong D., et al. HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 2002, 54:1537-1549.
42. Hutchison G.J., Valentine H.R., Loncaster J.A., et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004, 10:8405-8412.
43. Elvidge G.P., Glenny L., Appelhoff R.J., et al. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: The role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 2006, 281:15215-15226.
44. Marotta D., Karar J., Jenkins W.T., et al. In vivo profiling of hypoxic Gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Res 2011, 71:779-789.
45. Chi J.T., Wang Z., Nuyten D.S., et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3:e47.
46. Winter S.C., Buffa F.M., Silva P., et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67:3441-3449.
47. Buffa F.M., Harris A.L., West C.M., et al. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010, 102:428-435.
48. Denko N.C., Fontana L.A., Hudson K.M., et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003, 22:5907-5914.
49. Seigneuric R., Starmans M.H., Fung G., et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 2007, 83:374-382.
50. Toustrup K., Sørensen B.S., Nordsmark M., et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 2011, 71:5923-5931.
51. Sørensen B.S., Toustrup K., Horsman M.R., et al. Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. Acta Oncol 2010, 49:895-905.
52. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996, 41:31-39.
53. Nordsmark M., Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000, 57:39-43.
54. Sørensen B.S., Hao J., Overgaard J., et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 2005, 76:187-193.
55. Toustrup K., Sørensen B.S., Lassen P., et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012, 102(1):122-129.
56. Lassen P., Eriksen J.G., Hamilton-Dutoit S., et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009, 27:1992-1998.
57. Lassen P., Eriksen J.G., Hamilton-Dutoit S., et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010, 94:30-35.
58. Kong C.S., Narasimhan B., Cao H., et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009, 74:553-561.
59. Diehn M., Cho R.W., Lobo N.A., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
60. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8:545-554.
61. Bohmann K., Hennig G., Rogel U., et al. RNA extraction from archival formalin-fixed paraffin-embedded tissue: A comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 2009, 55:1719-1727.
62. Hennig G., Gehrmann M., Stropp U., et al. Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem 2010, 56:1845-1853.
63. Grau C., Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 1988, 13:301-309.
64. Higgins J.P., Shinghal R., Gill H., et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003, 162:925-932.
65. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
66. van de Vijver M.J., He Y.D., vanD́t Veer L.J., et al. A gene expression signature as a predictor of survival in breast cancer. N Eng J Med 2002, 347:1999-2009.
67. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555.
68. Chung C.H., Parker J.S., Karaca G., et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004, 5:489-500.
69. Cromer A., Carles A., Millon R., et al. Identification of genes associated with tumorigenesis and metastatic potential of hyopharyngeal cancer by microarray analysis. Oncogene 2004, 23:2484-2498.
70. Peyon D., Newton M.A., Lambert P.F., et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007, 67:4605-4619.
71. Loi S., Haibe-Kains B., Desmedt C., et al. Predicting prognosis using molecular profiling in estrogen receptor positive breast cancer treated with tamoxifen. BMC genomics 2008, 9:239.
72. Carroll J.S., Meyer C.A., Song J., et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006, 38:1289-1297.
73. Beer D.G., Kardia S.L., Huang C.C., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
74. Raponi M., Zhang Y., Yu J., et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006, 66:7466-7472.